When Emma was diagnosed with triple-negative breast cancer, she didn't let it define her. There are so many ways cancer steals possibility, but at Gilead, we’re helping take it back.
At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them most. In our latest episode of The Centrifuge Sessions, Magdeleine Hung, Director of Protein Therapeutics, shares insights on our pioneering work in HIV.
GileadNews: We’re joining with Kite Pharma to announce the presentation of transformative cancer research at this year’s American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings.
We’re proud to share that “The Adventure Jar,” a children’s book supporting families impacted by metastatic breast cancer (MBC), has received two 2025 Bronze Anvil Awards from the Public Relations Society of America (PRSA).
“Living with primary biliary cholangitis (PBC) can be an isolating experience,” explains Dilek, a mother of two from Germany who suffers from the rare chronic liver disease.
Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to ensure our medicines are delivered in ways that safeguard the planet.
At Gilead, we innovate for impact. This commitment helps us drive scientific solutions forward, reach more people in more places and protect the planet we all share.
Congratulations to our very own Tomas Cihlar, Senior Vice President of Research, Virology, for being named to TIME's list of the 100 Most Influential People in the World.
Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu – an online mapping tool that visualizes granular data
At Gilead, we set and achieve bold ambitions in our fight against the world’s most devastating diseases. In this installment of The Centrifuge Sessions, See Phan, Vice President, Oncology Clinical Development
At Gilead, we’re focused on fighting devastating diseases and delivering innovative medicines that offer new hope for patients. Also important, though, is our work to make sure that we remove barriers to care and reach the people that need our therapies.
Long-time liver specialist Carrie Frenette says she won’t ever forget the people she treated for hepatitis C (HCV) before 2013 – the year that the Food and Drug Administration (FDA) approved a Gilead medicine. The medicine was the first curative therapy for HCV.
We’re proud to offer an inclusive culture that enables all people to do their best work, and we’re happy to be named one of Newsweek America’s Greatest Workplaces for Diversity for our efforts.
The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer – and the challenges they face due to stigma and health inequities – come together in the form of a new, intentionally difficult-to-read book from Gilead.
For the past 30 years, Pilar Fernandez has navigated living with metastatic breast cancer. And while she’s faced a series of related health challenges, it hasn’t slowed her down.
When employees at Gilead’s recently opened New Jersey office need a place to meet, the “Cara” conference room is one such place they gather. Given the room’s namesake, it’s especially fitting when the topic at hand is the company’s oncology work.
Gilead Sciences, Inc. (Nasdaq: GILD) announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year.
Gilead Sciences, Inc. announced it will present new data at San Antonio Breast Cancer Symposium 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer and pre-treated HR+/HER2- metastatic breast cancer patients.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...